ArticleFrontiers in pharmacology2025
Low-dose statins restore innate immune response in breast cancer cells via suppression of mutant p53.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Therapy-Induced Senescence (TIS) and SASP: The p53-Mediated Interplay in Cancer Progression and Treatment.International journal of molecular sciences · 2025Review
- Emerging Roles of PTTG1/Securin in Breast Cancer.Journal of Cancer · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Breast cancer's high recurrence and treatment side effects demand safer, more effective therapies. Mutations in the critical TP53 gene, which normally prevents cancer, can instead promote it. This study explores if low-dose statins can curb mutant p53 activation in breast cancer's immune signaling, hindering tumor immune evasion. Methods: The study used diverse breast cancer cell lines with varying p53 statuses. Techniques included Western blot, transfection, qRT-PCR, co-immunoprecipitation, nuclear fractionation, and immunohistochemistry. Results: The study found that suppressing mutant p53 restores innate immunity and enhances cancer treatment. Low-dose statins promoted IRF3 nuclear translocation by inhibiting mutant p53. Lovastatin treatment Conclusion: The findings suggest low-dose statins can enhance innate immunity in breast cancer by degrading mutant p53, offering new treatment possibilities. Caution is advised, and further research is needed to address limitations and provide solid evidence for clinical use.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.